TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of a scientific abstract reporting the results of the NATESTO® Spermatogenesis Study by the Endocrine Society for presentation at their Annual Meeting.
Thomas Masterson, MD, Urology Fellow in the Department of Urology at the University of Miami School of Medicine, will present the NATESTO® clinical study results during a poster session at ENDO 2020, which will be held in San Francisco, CA March 28-31, 2020.
The NATESTO® Spermatogenesis Study has been conducted under the direction of principal investigator Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology, Department of Urology, University of Miami School of Medicine.
- Presenting Author: Thomas Masterson, MD, Fellow, Department of Urology, University of Miami School of Medicine
- Presentation Title: The Effect of NATESTO® on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms: A Phase IV Study
- Abstract Number: 5238
Additionally, Dr. Masterson has been selected to receive an Outstanding Abstract Award in conjunction with ENDO 2020 for this abstract.
All abstracts presented at ENDO 2020 will be published after the conclusion of ENDO 2020 in the Journal of the Endocrine Society.
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Notice Regarding Forward-Looking Statements
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO® and the impact of the Spermatogenesis study on such performance, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.